Soft Tissue Infections Clinical Trial
Official title:
Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures That Dictate Severity of Tissue Infection
This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with high morbidity and mortality. The fulminant course of NSTIs demands immediate diagnosis and adequate interventions in order to salvage lives and limbs. However, diagnosis and management are difficult due to heterogeneity in clinical presentation, in co-morbidities and in microbiological aetiology. Thus, there is an urgent need for novel diagnostics and therapeutics in order to improve outcome of NSTIs. A comprehensive knowledge of diagnostic features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host and bacterial disease traits and their underlying interaction network) is required for an improved diagnosis and management of NSTIs. The current proposal is designed to obtain such insights through an integrated systems biology approach in patients and experimental models. The project is based on a prospective NSTI patients cohort including a clinical registry to document clinical data and treatment strategies, combined with an isolate and biobank collection. The samples will be analyzed through advanced bioinformatics and computational modelling work flow to identify and quantify pathogen signatures and underlying networks that contribute to disease outcome. One aim is to translate clinical and systems biology data into development of novel diagnostics.
Patients will be prospectively recruited at 5 clinical centers (Rigshospitalet, Karolinska
University Hospital, Blekinge University, Sahlgrenska University and University of Bergen).
Clinical definition criteria for NSTI: NSTI is a clinical diagnosis. Initial signs are the
occurrence of erythema, pain or tenderness beyond margins of erythema and swelling. Imaging
and laboratory tests have little predictive value in the early stage. The gold standard
modality for diagnosis of NSTI remains operative exploration. Operative findings that are
consistent with NSTI include "dishwater or foul smelling discharge, necrosis or lack of
bleeding and loss of the normal resistance of the fascia to finger dissection. A patient
admitted for critical care and / or surgery due to severe soft tissue infection of the
fascia, muscle or subcutaneous tissues will be enrolled in this NSTI study. The patients will
be stratified based on several clinical parameters including among others SAPS score,
presence of multiorgan failure, and hypotensive shock. This stratification serves to classify
the patients in defined severity classes to be used in analyses and modeling. Detailed
demographic and clinical information will be documented in the interactive database
including: age, gender, medical history, clinical presentation (shock, multiorgan failure
etc), treatment and outcome. Disease progress: The clinical database is to contain
information on the spread of the infection at the different times of inspection/surgical
intervention. Severity of the infections will be documented by use of the updated CREST
classification scheme, SAPS III score, and the LRINEC score. Detailed information regarding
antimicrobial therapy, surgical intervention, innovative therapy (IVIG and HBO) will be
documented.
Samples will be collected from all enrolled patients. Standard operating procedures will be
generated and implemented at all sites to ensure a quality assured collection and handling of
samples. Samples to be collected include (a) isolates, (b) blood samples to be processed for
DNA, RNA and plasma/cells and (c) tissue biopsies in all patients whenever surgical
interventions are indicated. The samples will be analyzed using genomics, transcriptomics,
metabolomics and proteomics.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04332679 -
Non-resorbable Membranes Versus Titanium Meshes and Resorbable Membranes
|
N/A | |
Completed |
NCT00187759 -
Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection
|
N/A | |
Completed |
NCT02097615 -
Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water
|
Phase 4 | |
Completed |
NCT01557426 -
Soft Tissue Ultrasound of Infections
|
Phase 1 | |
Active, not recruiting |
NCT04257097 -
Reinforced PTFE Meshes Versus Customized Titanium Meshes
|
N/A | |
Enrolling by invitation |
NCT05826873 -
Discharge Stewardship in Children's Hospitals
|
N/A | |
Completed |
NCT04393909 -
Improving Safety of Diagnosis and Therapy in the Inpatient Setting
|
N/A | |
Active, not recruiting |
NCT02595047 -
Autologous Prefabrication of Body Surface Tissues/ Organs(e.g. Joint)
|
N/A | |
Completed |
NCT00785200 -
MRSA Colonization and Control in the Dallas County Jail
|
N/A | |
Completed |
NCT00426933 -
Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Terminated |
NCT00102947 -
Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections
|
Phase 4 | |
Completed |
NCT00451386 -
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
|
Phase 2 | |
Completed |
NCT03643952 -
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
|
Phase 2 | |
Recruiting |
NCT02979951 -
Fosfomycin i.v. for Treatment of Severely Infected Patients
|
||
Completed |
NCT02600871 -
Skin and Soft Tissue Infection (SSTI) Study
|
Phase 4 | |
Completed |
NCT00303589 -
A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT04286334 -
Three-dimensional Bone Regeneration Using Custom-made Meshes With and Without Collagen Membrane
|
N/A | |
Recruiting |
NCT05471908 -
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
|
N/A | |
Withdrawn |
NCT03982030 -
Dalbavancin Outpatient Pilot
|
Phase 4 | |
Terminated |
NCT00430937 -
Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
|
Phase 3 |